Global economic burden of schizophrenia: a systematic review

Huey Yi Chong, Siew Li Teoh, David Bin-Chia Wu, Surachai Kotirum, Chiun-Fang Chiou, Nathorn Chaiyakunapruk, Huey Yi Chong, Siew Li Teoh, David Bin-Chia Wu, Surachai Kotirum, Chiun-Fang Chiou, Nathorn Chaiyakunapruk

Abstract

Background: Schizophrenia is one of the top 25 leading causes of disability worldwide in 2013. Despite its low prevalence, its health, social, and economic burden has been tremendous, not only for patients but also for families, caregivers, and the wider society. The magnitude of disease burden investigated in an economic burden study is an important source to policymakers in decision making. This study aims to systematically identify studies focusing on the economic burden of schizophrenia, describe the methods and data sources used, and summarize the findings of economic burden of schizophrenia.

Methods: A systematic review was performed for economic burden studies in schizophrenia using four electronic databases (Medline, EMBASE, PsycINFO, and EconLit) from inception to August 31, 2014.

Results: A total of 56 articles were included in this review. More than 80% of the studies were conducted in high-income countries. Most studies had undertaken a retrospective- and prevalence-based study design. The bottom-up approach was commonly employed to determine cost, while human capital method was used for indirect cost estimation. Database and literature were the most commonly used data sources in cost estimation in high-income countries, while chart review and interview were the main data sources in low and middle-income countries. Annual costs for the schizophrenia population in the country ranged from US$94 million to US$102 billion. Indirect costs contributed to 50%-85% of the total costs associated with schizophrenia. The economic burden of schizophrenia was estimated to range from 0.02% to 1.65% of the gross domestic product.

Conclusion: The enormous economic burden in schizophrenia is suggestive of the inadequate provision of health care services to these patients. An informed decision is achievable with the increasing recognition among public and policymakers that schizophrenia is burdensome. This results in better resource allocation and the development of policy-oriented research for this highly disabling yet under-recognized mental health disease.

Keywords: cost of illness; economic burden; schizophrenia; systematic review.

Figures

Figure 1
Figure 1
Flow diagram of the selection process to identify studies to be included.

References

    1. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 386(9995):743–800.
    1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
    1. World Health Organization (WHO) Mental Health: New Understanding, New Hope. Geneva: WHO; 2001.
    1. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res. 1997;28(2–3):111–125.
    1. Barbato A. Schizophrenia and Public Health. Geneva: World Health Organization; 1998.
    1. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173–180.
    1. Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010;8:24.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
    1. Brundtland GH. Mental health in the 21st century. Bull World Health Organ. 2000;78(4):411–411.
    1. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122–1129.
    1. Chang SM, Cho S-J, Jeon HJ, et al. Economic burden of schizophrenia in South Korea. J Korean Med Sci. 2008;23(2):167–175.
    1. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry. 1995:S60–S67.
    1. Millier A, Shupo F, Chauhan D, Toumi M. PMH17 Economic burden in schizophrenia: a literature review. Val Health. 2012;15(7):A336.
    1. PRISMA Conceptual issues in the evolution from QUORUM to PRISMA. [Accessed January 14, 2015]. Available from: .
    1. International Monetary Fund . World Economic Outlook Database 2013. Washington, DC: International Monetary Fund; 2013.
    1. FxTop Currency converter. [Accessed November 7, 2014]. Available from: .
    1. Saha S, Gerdtham UG. Cost of illness studies on reproductive, maternal, newborn, and child health: a systematic literature review. Health Econ Rev. 2013;3(1):24.
    1. Rice DP, Miller LS. The economic burden of schizophrenia: Conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of Mental Economics and Health Policy. Vol. 1. London: Wiley; 1996. pp. 321–334. (Schizophrenia).
    1. Mogyorosy Z, Smith P. The Main Methodological Issues in Costing Health Care Services: A Literature Review. York: Center for Health Economics, University of York; 2005.
    1. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014;105(2):151–163.
    1. Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rossler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16(4):337–353.
    1. Wimo A, Jönsson L, Gustavsson A. Health economics aspects of dementia. [Accessed November 4, 2015]. Available from: .
    1. Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol. 2004;22(6):699–706.
    1. Castro DM, Dillon C, Machnicki G, Allegri RF. The economic cost of Alzheimer’s disease: family or public health burden? Dement Neuropsychol. 2010;4(4):262–267.
    1. Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1083–1090.
    1. Dadoun S, Guillemin F, Lucier S, et al. Work productivity loss in early arthritis during the first 3 years of disease: a study from a French national multicenter cohort. Arthritis Care Res. 2014;66(9):1310–1318.
    1. Modi P, Suvarna K, Cooper GJ. Images in cardiology. Descending thoracic aortic aneurysm in rheumatoid arthritis. Heart. 2000;84(2):122.
    1. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39(1):28–33.
    1. Saldivia Borquez S, Torres Gonzalez F, Cabases Hita JM. Estimation of mental health care cost units for patients with schizophrenia. Actas Esp Psiquiatr. 2005;33(5):280–285.
    1. De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull. 1998;24(4):519–527.
    1. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl. 1994;165(25):18–21.
    1. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M. The societal cost of schizophrenia in Sweden. J Ment Health Policy Econ. 2013;16(1):13–25.
    1. Frey S. The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. Eur Psychiatry. 2014;29:479–489.
    1. Garattini L. Direct costs of schizophrenia in Italian community psychiatric services. Pharmacoeconomics. 2001;19(12):1217–1225.
    1. Garattini L, Barbui C, Clemente R, Cornago D, Parazzini F. Direct costs of schizophrenia and related disorders in Italian community mental health services: a multicenter, prospective 1-year followup study. Schizophr Bull. 2004;30(2):295–302.
    1. Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics. 1999;15(6):597–610.
    1. Haro JM, Salvador-Carulla L, Cabases J, Madoz V, Vazquez-Barquero JL. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry. 1998;173:334–340.
    1. Heider D, Bernert S, Konig HH, et al. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom – Findings from the European Schizophrenia Cohort (EuroSC) Eur Psychiatry. 2009;24(4):216–224.
    1. Hertzman P. The economic costs of mental illness in Sweden 1975. Acta Psychiatr Scand. 1983;68(5):359–367.
    1. Knapp M, Chisholm D, Leese M, et al. Comparing patterns and costs of schizophrenia care in five European countries: The EPSILON study. Acta Psychiatr Scand. 2002;105(1):42–54.
    1. Lindstrom E, Eberhard J, Neovius M, Levander S. Costs of schizophrenia during 5 years. Acta Psychiatr Scand Suppl. 2007;116:33–40.
    1. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10(1):23–41.
    1. Oliva-Moreno J, Lopez-Bastida J, Osuna-Guerrero R, Montejo-Gonzalez AL, Duque-Gonzalez B. The costs of schizophrenia in Spain. Eur J Health Econ. 2006;7(3):182–188.
    1. Rouillon F. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics. 1997;11(6):578–594.
    1. Rund BR, Ruud T. Costs of services for schizophrenic patients in Norway. Acta Psychiatr Scand. 1999;99(2):120–125.
    1. Salize HJ, McCabe R, Bullenkamp J, et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res. 2009;111(1–3):70–77.
    1. Salize HJ, Rossler W. The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br J Psychiatry. 1996;169:42–48.
    1. Sarlon E, Heider D, Millier A, et al. A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Serv Res. 2012;12:269–276.
    1. Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy: The GISIES study. Health Policy. 2000;51(1):1–18.
    1. Vazquez-Polo FJ, Negrin M, Cabases JM, Sanchez E, Haro JM, Salvador-Carulla L. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ. 2005;8(3):153–165.
    1. Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev. 2012;2(1):1–8.
    1. Behan C, Kennelly B, O’Callaghan E. The economic cost of schizophrenia in Ireland: a cost of illness study. Irish J Psychol Med. 2008;25(3):80–87.
    1. Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull. 1995;21(1):141–153.
    1. Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically Ill patients. Am J Geriatr Psychiatry. 2003;11(6):648–657.
    1. Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health. 2001;28(5):335–351.
    1. Cuffel BJ, Jeste DV, Halpain M, Pratt C, Tarke H, Patterson TL. Treatment costs and use of community mental health services for schizophrenia by age cohorts. Am J Psychiatry. 1996;153(7):870–876.
    1. Desai PR, Lawson KA, Barner JC, Rascati KL. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Ser Res. 2013;4(4):187–194.
    1. Dixon L, Lyles A, Smith C, et al. Use and costs of ambulatory care services among medicare enrollees with schizophrenia. Psychiatr Serv. 2001;52(6):786–792.
    1. Feldman R, Bailey RA, Muller J, Le J, Dirani R. Cost of schizophrenia in the medicare program. Popul Health Manag. 2014;17(3):190–196.
    1. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21(12):2017–2028.
    1. Leslie DL, Rosenheck R. Shifting to outpatient care? Mental health care use and cost under private insurance. Am J Psychiatry. 1999;156(8):1250–1257.
    1. Martin BC, Miller LS. Expenditures for treating schizophrenia: a population-based study of Georgia medicaid recipients. Schizophr Bull. 1998;24(3):479–488.
    1. McDonald M, Hertz RP, Lustik MB, Unger AN. Healthcare spending among community-dwelling adults with schizophrenia. Am J Manag Care. 2005;11:S242–S247.
    1. Miller LS, Martin BC. Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the State of Georgia. Schizophr Bull. 2004;30(4):983–995.
    1. Rubio-Stipec M, Stipec B, Canino G. The costs of schizophrenia in Puerto Rico. J Ment Health Adm. 1994;21(2):136–144.
    1. Leitao RJ, Ferraz MB, Chaves AC, Mari JJ. Cost of schizophrenia: direct costs and use of resources in the State of Sao Paulo. Rev Saude Publica. 2006;40(2):304–309.
    1. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia-1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30(5):196–205.
    1. Gunderson JG, Mosher LR. The cost of schizophrenia. Am J Psychiatry. 1975;132(9):901–906.
    1. de Silva J, Hanwella R, de Silva VA. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. Ceylon Med J. 2012;57(1):14–18.
    1. Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry. 2003;37(1):31–40.
    1. Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P. Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta Psychiatr Scand. 2005;112(1):54–63.
    1. Hall W, Goldstein G, Andrews G, Lapsley H, Bartels R, Silove D. Estimating the economic costs of schizophrenia. Schizophr Bull. 1985;11(4):598–610.
    1. Lang HC, Su TP. The cost of schizophrenia treatment in Taiwan. Psychiatr Serv. 2004;55(8):928–930.
    1. Lee IH, Chen PS, Yang YK, et al. The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res. 2008;158(3):306–315.
    1. Pahuja S, Aboobacker S, Shini VK. Schizophrenia – cost of illness. Int J Pharm Sci Rev Res. 2011;6(1):55–59.
    1. Phanthunane P, Whiteford H, Vos T, Bertram M. Economic burden of schizophrenia: empirical analyses from a survey in Thailand. J Ment Health Policy Econ. 2012;15(1):25–32.
    1. Sado M, Inagaki A, Koreki A, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat. 2013;9:787–798.
    1. Zhai J, Guo X, Chen M, Zhao J, Su Z. An investigation of economic costs of schizophrenia in two areas of China. Int J Ment Health Syst. 2013;7(1):26.
    1. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther. 1997;19(6):1470–1495.
    1. Fitzgerald PB, Montgomery W, de Castella AR, et al. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust N Z J Psychiatry. 2007;41(10):819–829.
    1. Amoo G, Ogunlesi AO. Financial cost of treating Nigerian in-patients with schizophrenia. Afr J Med Med Sci. 2005;34(1):15–23.
    1. Suleiman TG, Ohaeri JU, Lawal RA, Haruna AY, Orija OB. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry. 1997;171:364–368.
    1. Segel JE. Cost-of-illness studies – A primer. RTI-UNC Center of Excellence in Health Promotion Economics. 2006:1–39.
    1. Kigozi J, Jowett S, Lewis M, Barton P, Coast J. Estimating productivity costs using the friction cost approach in practice: a systematic review. Eur J Health Econ. 2016;17(1):31–44.
    1. O’Shea E, Kennelly B. The Economics of Mental Health Care in Ireland. Dublin: Mental Health Commission; 2008.
    1. Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoeconomics Outcomes Res. 2013;5:565–573.
    1. Millier A, Schmidt U, Angermeyer M, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.
    1. Hu TW. Perspectives: an international review of the national cost estimates of mental illness, 1990–2003. J Ment Health Policy Econ. 2006;9(1):3–13.
    1. Freeman P, Robbins A. The publishing gap between rich and poor: the focus of AuthorAID. J Public Health Policy. 2006;27:196–203.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit